Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes by 源��쁺�� et al.
ORIGINAL RESEARCH
published: 18 December 2018
doi: 10.3389/fneur.2018.01095
Frontiers in Neurology | www.frontiersin.org 1 December 2018 | Volume 9 | Article 1095
Edited by:
Antonio Arauz,
Instituto Nacional de Neurología y
Neurocirugía (INNN), Mexico
Reviewed by:
Christoph Gumbinger,
Universität Heidelberg, Germany
Henry Ma,
Monash University, Australia
*Correspondence:
Young Dae Kim
neuro05@yuhs.ac
Specialty section:
This article was submitted to
Stroke,
a section of the journal
Frontiers in Neurology
Received: 15 October 2018
Accepted: 29 November 2018
Published: 18 December 2018
Citation:
Park JH, Han SW, Lee K-Y, Choi H-Y,
Cheon K, Cho H-J, Jung YH, Park HJ,
Nam HS, Heo JH, Lee HS,
Saposnik G and Kim YD (2018) Impact
of Non-vitamin K Antagonist Oral
Anticoagulant Withdrawal on Stroke
Outcomes. Front. Neurol. 9:1095.
doi: 10.3389/fneur.2018.01095
Impact of Non-vitamin K Antagonist
Oral Anticoagulant Withdrawal on
Stroke Outcomes
Joong Hyun Park 1, Sang Won Han 1, Kyung-Yul Lee 2, Hye-Yeon Choi 3,
Kyeongyeol Cheon 2, Han-Jin Cho 4, Yo Han Jung 5, Hyung Jong Park 6, Hyo Suk Nam 6,
Ji Hoe Heo 6, Hye Sun Lee 7, Gustavo Saposnik 8 and Young Dae Kim 6*
1Department of Neurology, Inje University College of Medicine, Seoul, South Korea, 2Department of Neurology, Gangnam
Severance Hospital, Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul,
South Korea, 3Department of Neurology, Kyung Hee University School of Medicine, Kyung Hee University Hospital, Seoul,
South Korea, 4Department of Neurology, Pusan National University Hospital, Pusan National University College of Medicine
and Biomedical Research Institute, Busan, South Korea, 5Department of Neurology, Changwon Fatima Hospital, Changwon,
South Korea, 6Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea, 7Biostatistics
Collaboration Unit, Yonsei University College of Medicine, Seoul, South Korea, 8 Stroke Outcomes and Decision
Neuroscience Research Unit, Division of Neurology, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada
Introduction: Discontinuation of oral anticoagulants such as non-vitamin K antagonist
oral anticoagulants (NOACs) may induce a hypercoagulable state, leading to severe
stroke and poor outcomes. This study aimed to compare stroke outcomes between
NOACs withdrawal and other prior medication statuses in patients with non-valvular atrial
fibrillation (NVAF).
Methods: Consecutive patients who had pre-existing NVAF and were admitted for an
acute ischemic stroke or transient ischemic attack- at five hospitals between January
2013 and December 2016 were included. Prior medication status was categorized into
seven groups such as no antithrombotics, antiplatelet-only, warfarin with subtherapeutic
intensity, warfarin with therapeutic intensity, NOAC, warfarin withdrawal, and NOAC
withdrawal. We compared initial National Institute of Health Stroke Scale (NIHSS) scores
between groups
Results: Among 719 patients with NVAF, The median NIHSS score at admission was
5 (IQR 1-13). The NOAC withdrawal group had the highest median NIHSS scores at
stroke onset [16, interquartile range, IQR (1–17)], followed by the warfarin withdrawal
group [11, IQR (1–14, 18)], the no antithrombotic group [5, IQR (1–13, 18, 19)], and
the warfarin with subtherapeutic intensity group [5, IQR (1–10, 18, 19)]. A Multivariable
analysis demonstrated that NOAC withdrawal was independently associated with higher
NIHSS scores at stroke onset (B 4.645, 95% confidence interval 0.384–8.906, P =
0.033). The median interval from drug withdrawal to ischemic stroke or TIA was 7 days
(IQR 4-15) in the NOAC group.
Conclusions: Stroke that occurred after stopping oral anticoagulants, especially NOAC,
and was more severe at presentation and associated with poorer outcomes.
Keywords: stroke, non-valvular atrial fibrillation, outcome, cardiac embolism, anticoagulation
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INTRODUCTION
Non-valvular atrial fibrillation (NVAF) is the most common
etiology of cardioembolic ischemic stroke (20). Although NVAF-
related stroke is associated with an increased risk of stroke or
fatal stroke, oral anticoagulationmay effectively prevent ischemic
events including an ischemic stroke or a transient ischemic attack
(TIA) (19). Following the publication of studies which showed
the benefits of non-vitamin K oral anticoagulants (NOACs)
compared to warfarin, NOACs became widely used in clinical
practice worldwide (1, 18).
The discontinuation of antithrombotics can be associated with
an increased risk of cardiovascular events and poor outcomes
(2, 3). Abrupt warfarin withdrawal may induce a rebound
or a paradoxical prothrombotic state, subsequently leading to
an increased incident risk of stroke for up to 3 months (4).
Considering the potent anticoagulant effect of NOACs on the
suppression of thrombogenesis, NOAC withdrawal may also be
associated with severe stroke at presentation and poor outcomes
in NVAF-related stroke. However, to date, there is limited
information on the existence of this phenomenon.
The aim of this study was to compare the initial stroke severity
associated with NOAC withdrawal to those associated with
other prior medication statuses including warfarin withdrawal in
patients with NVAF.
METHODS
Study Population
We retrospectively reviewed the medical records of consecutive
patients with an acute ischemic stroke or TIA and NVAF, who
were admitted within 7 days at the Department of Neurology
at four regional stroke centers (Severance Stroke Center,
Gangnam Severance Stroke Center, Kyung Hee University
Hospital Stroke Center, and Inje Paik Hospital) and one general
hospital (Changwon Fatima Hospital) between January 2013 and
December 2016. During hospitalization, all patients underwent
brain imaging and were managed through a standardized
care pathway based on current guidelines. For each patient,
demographic data, previousmedical history, vascular risk factors,
clinical manifestations, standard blood tests, and underlying
vascular disease were systematically investigated.
This study was approved by the institutional review board at
each participating hospital, and the requirement for informed
consent was waived because the database was accessed only for
analysis purposes and personal information was not used.
Clinical Information
We collected data on demographics and traditional vascular risk
factors such as hypertension, diabetes, dyslipidemia, and current
smoking status (5). History of previous ischemic heart disease,
congestive heart failure, peripheral arterial occlusive disease, or
ischemic stroke was also investigated. TIA was defined as a
transient episode of neurologic dysfunction caused by focal brain
or retinal ischemia without acute infarction on a brain MRI
including diffusion-weighted imaging. Data on international
normalized ratio (INR) levels, lipid profile at admission, and
creatinine clearance rate using the Cockcroft-Gault equation
were collected. The blood levels of the NOACs were not
measured in this study. We also calculated the CHA2DS2-VASc
score in all patients based on their comorbid conditions (6).
In patients with acute ischemic lesions on the brain imaging,
we determined whether the stroke mechanism was caused by
cardioembolism or if it had more than two causes according to
the Trial of Org 10172 in Acute Stroke Treatment classification
(7).
Medication Status
Based on medical records or interviews with the patients or
their next of kin or caregiver, we determined the medication
that was taken prior to the index stroke. Using data on the
medications used prior to the stroke and the laboratory results
at stroke presentation, we categorized the patients into seven
groups as follows: (1) no antithrombotics, (2) antiplatelet-only,
(3) warfarin with subtherapeutic intensity (INR<2), (4) warfarin
with therapeutic intensity (INR≥2), (5) NOAC, (6) warfarin
withdrawal, and (7) NOAC withdrawal. Warfarin withdrawal
and NOAC withdrawal were defined as those patients who had
previously taken an oral anticoagulant but had discontinued the
drug within 2 months before the index stroke (8). If a patient had
stopped taking warfarin or NOACs, we determined the reason
for the discontinuation. We also collected data on the prior use
of statins before the index stroke.
Outcome Measures
We collected data on the initial stroke severity at stroke
presentation. The neurological status of each patient during
hospitalization was determined regularly at our study centers
using the National Institute of Health Stroke Scale (NIHSS)
scores which were obtained by a senior neurology resident or
stroke specialist.
Statistical Analyses
Statistical analysis was performed using the Windows SPSS
package (version 23.0, IBM Corp., Armonk, NY, USA) and the
R package (version 3.1.0, http://www.R-project.org). Categorical
variables between groups were compared using the chi-square
test or Fisher’s exact test, while the independent t-test or Kruskall-
Wallis test was used for the comparison of continuous variables.
When we investigated whether NIHSS scores differed between
the groups, Tobit analysis was used to determine the factors
influencing initial stroke severity. Tobit regression was used to
address the ceiling and floor effects noted in clinical outcomes
(9). Using Tobit regression analysis adjusted for the potential
confounders (P < 0.05 on univariable analysis), the independent
association between prior antithrombotics and stroke severity
was evaluated. Results were expressed as B (95% confidence
intervals [CIs]) with the no antithrombotics group as the
reference group. Finally, statistical significance was set at P <
0.05.
RESULTS
Baseline Characteristics
Of the 1,361 patients with atrial fibrillation who were admitted
at the study hospitals during the study period, we excluded the
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patients with valvular heart disease (n= 66) and those with atrial
fibrillation detected for the first time at hospitalization (n= 576).
Finally, 719 patients with pre-existingNVAF (707 ischemic stroke
and 12 TIA) were included in this study.
Mean age was 73.9±10.2 years, and 397 (55.2%) patients were
male. Median CHA2DS2-VASc score was 4 (interquartile range
[IQR] 3-5). There were 16 patients in the NOAC withdrawal
group, 47 in the warfarin withdrawal group, 57 in the NOAC
group, 31 in the warfarin with therapeutic intensity group, 130
in the warfarin with subtherapeutic intensity group, 298 in
the antiplatelet-only group, and 140 in the no antithrombotic
group. Differences in baseline characteristics are summarized
in Table 1. The NOAC withdrawal group was more likely to
have hypertension and higher CHA2DS2-VASc scores, while the
NOAC group was more likely to have a history of ischemic
heart disease or ischemic stroke and prior statin use (all
P<0.05).
NOAC or Warfarin Withdrawal Group
The median interval from drug withdrawal to ischemic stroke
or TIA was 7 days (IQR 4-15) in the NOAC group and 9 days
(IQR 5-20) in the warfarin group (Figure 1). Among the 16
patients who had a stroke after NOAC withdrawal, it occurred
in 6 patients after dabigatran discontinuation, 3 after apixaban
discontinuation, and 7 after rivaroxaban discontinuation. Among
the reasons for NOAC or warfarin cessation, recent bleeding
event or self-discontinuation of drug without any specific
medical reason was common (Table 2).
Initial Stroke Severity According to the
Prior Medication Status
The median NIHSS score at admission was 5 (IQR 1-13).
The NOAC withdrawal group had the highest median NIHSS
score [16, IQR (1–17)], followed by the warfarin withdrawal
TABLE 1 | Baseline characteristics of study population according to prior medication status.
No
antithrombotics
(n = 140)
Antiplatelet-only
(n = 298)
Warfarin with
subtherapeutic
intensity
(n = 130)
Warfarin
with
therapeutic
intensity
(n = 31)
NOAC
(n = 57)
Warfarin
withdrawal
(n = 47)
NOAC
withdrawal
(n = 16)
P
Age 72.8 ± 12.1 74.3 ± 10.2 74.1 ± 9.3 75.9 ± 7.8 74 ± 8.7 71.9 ± 10.1 76.5 ± 9.0 0.418
Male 84 (60.0) 166 (55.7) 68 (52.3) 21 (67.7) 24 (42.1) 25(53.2) 9 (56.2) 0.254
Congestive heart failure 25 (17.9) 42 (14.1) 17 (13.1) 8 (25.8) 3 (5.3) 10 (21.3) 3 (18.8) 0.084
Hypertension 98 (70.0) 239 (80.2) 106 (81.5) 29 (93.5) 51 (89.5) 37 (78.7) 15 (93.8) 0.007
Diabetes 39 (27.9) 84 (28.2) 41 (31.5) 5 (16.1) 24 (42.1) 15 (31.9) 3 (18.8) 0.205
Dyslipidemia 27 (19.3) 74 (24.8) 22 (16.9) 11 (35.5) 12 (21.1) 8 (17.0) 6 (37.5) 0.12
Current smoking status 16 (11.4) 31 (10.4) 20 (15.4) 3 (9.7) 5 (8.8) 4 (8.5) 1 (6.2) 0.809
Previous ischemic heart
disease
20 (14.3) 90 (30.2) 36 (27.7) 8 (25.8) 21 (36.8) 13 (27.7) 6 (37.5) 0.01
Peripheral arterial occlusive
diseases
5 (3.6) 16 (5.4) 8 (6.2) 3 (9.7) 8 (14.0) 3 (6.4) 0 (0.0) 0.159
Previous ischemic stroke 28 (20.0) 70 (23.5) 59 (45.4) 17 (54.8) 39 (68.4) 22 (46.8) 6 (37.5) <0.001
Prior statin use 17 (12.3) 118 (39.6) 60 (46.2) 15 (48.4) 34 (59.6) 26 (55.3) 8 (50.0) <0.001
Cardioembolic stroke
mechanism
120 (86.3) 248 (84.6) 105 (84.0) 2 (71.0) 50 (89.3) 36 (76.6) 15 (93.8) 0.181
Median CHA2DS2-VASc
score, median (IQR)
4 (2–5) 4 (3–5) 5 (3–6) 5 (4–6) 5 (4–7) 5 (3–5) 5 (3–5) <0.001
CHA2DS2-VASc score 0.001
0 9 (6.4) 6 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.4) 0 (0.0)
1 17 (12.1) 25 (8.4) 6 (4.6) 0 (0.0) 1 (1.8) 2 (4.3) 0 (0.0)
≥2 114 (81.4) 267 (89.6) 124 (95.4) 31 (100.0) 56 (98.2) 42 (89.4) 16 (100.0)
Laboratory findings
INR 1 ± 0.2 1 ± 0.1 1.4 ± 0.3 2.8 ± 0.8 1.2 ± 0.2 1.2 ± 0.5 1.1 ± 0.2 <0.001
Creatinine clearance rate 61 ± 26.1 59.7 ± 26.9 60.3 ± 24 55.5 ± 25.2 62.2 ± 21.5 55.2 ± 24 60.2 ± 22.3 0.769
Total cholesterol, mmol/L 4.4 ± 1.0 4.0 ± 1.0 4.0 ± 1.0 3.9 ± 1.0 3.9 ± 1.2 3.7 ± 1.0 3.8 ± 1.0 <0.001
Triglyceride, mmol/L 1.2 ± 1.0 1.1 ± 0.7 1.1 ± 0.6 1.1 ± 0.4 1.2 ± 0.9 1.2 ± 0.6 0.9 ± 0.3 0.646
High-density lipoprotein,
mmol/L
1.2 ± 0.4 1.1 ± 0.3 1.2 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.2 ± 0.3 0.176
Low-density lipoprotein,
mmol/L
2.6 ± 0.7 2.4 ± 0.9 2.3 ± 0.9 2.4 ± 0.9 2.3 ± 1.0 2.1 ± 0.8 2.2 ± 1.0 0.006
Data are presented as mean (standard deviation) or number (percentages).
NOAC, non-vitamin K oral anticoagulant; IQR, interquartile range; INR, international normalized ratio; NIHSS, National Institute of Health Stroke Scale.
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FIGURE 1 | The number of patients who stopped taking non-vitamin K antagonist oral anticoagulans (A) or warfarin (B) according to the duration (days) of the
discontinuation.
TABLE 2 | Reasons why oral anticoagulant stopped.
NOAC withdrawal
(n = 16)
Warfarin withdrawal
(n = 47)
Self-discontinuation without any
medical reason
5 (31.3) 28 (59.6)
Recent bleeding event 6 (37.5) 8 (17.0)
Dental procedure 3 (18.8) 3 (6.4)
Endoscopy 0 (0) 5 (10.6)
Scheduled biopsy 1 (6.3) 2 (4.3)
Surgery 1 (6.3) 1 (2.1)
Data are presented as number (percentages).
group [11, IQR (1–14, 18)], the no antithrombotic group [5,
IQR (1–13, 18, 19)], and the warfarin with subtherapeutic
intensity group [5, IQR (1–10, 18, 19)] (Figure 2A and Table 3).
When we categorized the stroke severity into three levels
such as low (NIHSS ≤ 6), moderate (NIHSS 7-15), and
severe (NIHSS ≥16), moderate to severe stroke was more
common in NOAC withdrawal or warfarin withdrawal group
(Figure 2B). There was no difference in initial NIHSS scores
according to the reason for either NOAC withdrawal or warfarin
withdrawal.
The multivariable Tobit regression analysis adjusting for the
CHA2DS2-VASc score and current smoking status showed that
NOAC withdrawal was independently associated with higher
NIHSS scores (B 4.645, 95% CI 0.384–8.906, P = 0.033), while
prior warfarin with therapeutic intensity (B −4.968, 95% CI
−8.273 to −1.663, P = 0.003) and antiplatelets only (B −1.918,
95% CI −3.606 to −0.23, P = 0.033) were associated with lower
NIHSS scores. The results remained consistent when we excluded
patients with TIA (n = 12) (Table 3) or defined the withdrawal
as stopping the drug within 1 month before the index stroke
(Supplementary Table 1).
DISCUSSION
We conducted a large cohort study, compriised of stroke patients
with NVAF, to determine the association of NOAC withdrawal
and stroke outcomes. Our study revealed that withdrawal of oral
anticoagulants, especially NOACs, was associated with higher
NIHSS scores at stroke presentation in patients with NVAF.
Stroke severity was relatively milder among patients on warfarin
with therapeutic intensity or antiplatelets only.
Although there are several studies regarding the risk of
thromboembolic events after stopping NOACs (2, 10, 11), the
present study is the first to examine stroke characteristics
in patients who experienced an ischemic stroke or TIA
after abrupt NOAC withdrawal. Previous reports showed
that abrupt discontinuation of anticoagulants could cause
a rebound phenomenon involving a significant increase in
procoagulant markers such as thrombin-antithrombin III
complex, fibrinopeptide A and subsequently enhance thrombosis
(4, 12, 13). In terms of NOAC withdrawal, some clinical trials,
along with several anecdotal reports on patients with deep vein
thrombosis or knee replacement surgery, suggested a potential
prothrombotic rebound phenomenon after NOAC withdrawal.
Most thromboembolic events occurred soon (median 1–2 weeks)
following the cessation of dabigatran or rivaroxaban (2, 10, 11, 14,
15). In our study, themedian interval betweenNOACwithdrawal
and ischemic events was also 7 days, which may imply the
occurrence of a rebound phenomenon associated with NOAC
withdrawal.
In our study, stroke severity at presentation was most severe
in the NOAC withdrawal group, followed by the warfarin
withdrawal group, while prior use of warfarin with therapeutic
intensity or antiplatelets alone were associated with lower NIHSS
scores. There are some potential explanations to understand this
phenomenon. Stroke severity in NVAF is strongly correlated
with thrombus characteristics determined by the prothrombotic
state in the left atrium and the anticoagulant activity (16, 17).
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FIGURE 2 | Difference in (A) initial National Institute of Health Stroke Scale (NIHSS) and (B) stroke severity according to the medication status. NOAC, non-vitamin K
antagonist oral anticoagulant.
TABLE 3 | Tobit regression analysis showing initial stroke severity according to medication status.
Univariable analysis Multivariable analysis* Multivariable analysis†
B (95% CI) P B (95% CI) P B (95% CI) P
Previous medication
No antithrombotics 1 1 1
Antiplatelet-only −1.584 (−3.283 to 0.115) 0.068 −1.918 (-3.606 to −0.23) 0.026 −1.829 (−3.493 to −0.165) 0.031
Warfarin with subtherapeutic intensity −0.666 (−2.687 to 1.355) 0.518 −1.021 (−3.042 to 1) 0.322 −0.581 (−2.582 to 1.42) 0.569
Warfarin with therapeutic intensity −4.359 (−7.693 to −1.025) 0.01 −4.968 (−8.273 to −1.663) 0.003 −4.656 (−7.906 to −1.406) 0.005
NOAC −1.904 (−4.505 to 0.697) 0.151 −2.365 (−4.958 to 0.228) 0.074 −2.396 (−4.956 to 0.164) 0.066
Warfarin withdrawal 2.844 (0.063 to 5.625) 0.045 2.599 (−0.149 to 5.347) 0.064 2.766 (0.065 to 5.467) 0.045
NOAC withdrawal 5.225 (0.917 to 9.533) 0.017 4.645 (0.384 to 8.906) 0.033 4.297 (0.114 to 8.48) 0.044
NOAC, non-vitamin K oral anticoagulant.
*Adjusted for significant variables in the univariable analysis (P < 0.05) for the entire population (including TIA patients).
†Adjusted for significant variables in the univariable analysis (P < 0.05) for the ischemic stroke patient group.
The anticoagulant effect of NOAC decreases rapidly after 12–
24 h (21). The transient hypercoagulable state caused by abrupt
anticoagulant withdrawal may enhance thrombogenesis, leading
to larger sized thrombi. Moreover, thrombin overproduced after
cessation of anticoagulation by itself may promote excitotoxic
neuronal injury (22, 23). Considering the higher NIHSS
scores in the NOAC withdrawal group than in the warfarin
withdrawal group, NOAC withdrawal may more strongly
suppress thrombin/thrombin activity generation. Together with
coagulation activity, thrombus formation in AF can be influenced
by other factors including platelet activity (24). The prior use of
antiplatelets may prevent thrombus formation in the left atrium
and be associated with a milder stroke, although it was not found
to be superior to the optimal anticoagulant therapy (25, 26).
These assumptions regarding changes in coagulation and platelet
activity support our results that demonstrate differences in stroke
severity at stroke presentation according to prior medication
status.
Although the NOACs have many benefits for clinical use
including a fixed dose without the need for frequent monitoring,
dietary precautions, and bridging therapy, NOAC use is not
always well-maintained in actual clinical practice (18, 27, 28).
Among patients requiring NOAC withdrawal because of a
planned invasive procedure, the duration of the medication
interruption seemed to be prolonged in clinical practice (2). In
our study cohort, many patients who stoppedmedication because
of a scheduled invasive procedure, did not re-start medication
for a prolonged period, as the time between anticoagulant
withdrawal and the ischemic event was found to be long (ranged
between 5–20 days in patients using NOACs and 3–56 days in
patients using warfarin). Furthermore, patients often stopped
anticoagulants without any medical reason. Current guidelines
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indicated that it is not necessary to discontinue anticoagulant
treatment during a low bleeding risk procedure such as dental
procedures or diagnostic endoscopy (29). In addition, 18% (3/18)
in the NOAC withdrawal group and 17% (8/47) in the warfarin
withdrawal group discontinued in these situations. In our study
population, 31% in the NOAC withdrawal group and 60% in the
warfarin withdrawal group had not specific a medical reason.
To improve adherence to medication, the implementation of
educational programs and tools to help identify the patients who
are more likely to be non-compliant is necessary (18).
Our study had several limitations. First, although we collected
data on prior medication status for each patient, there is a
possibility that some stroke patients were missed after stopping
medication owing to patients’ neurologic deficits, especially
language dysfunction. However, it was routine practice in our
study hospitals for physician or nurses to inquire about the prior
medication status at the time of admission with their next of
kin or caregiver as well as with the patients themselves. Second,
the number of patients included the NOAC withdrawal group
was not large in this retrospective study, which could lead to
selection bias. The number of TIA patients was also small. In this
study, TIA was diagnosed based on a tissue-based definition, not
a time-based definition. Previous studies demonstrated that the
acute ischemic lesion was detected in over 50% of TIA patients
(30). Nearly all patients underwent the brain magnetic resonance
image including DWI in this study. Further, although it was not
difficult for TIA patients to be admitted to the hospital in Korea,
there was still a possibility that TIA patients might be managed
on the outpatient clinic, rather than being hospitalized (31). This
might have led to the small number of TIA patients in our study
population. Third, we did not thoroughly investigate the reason
why oral anticoagulation was not resumed. Fourth, this study
enrolled only Korean patients, which limited the generalizability
of the study findings to other geographic regions or ethnic
groups.
Our findings demonstrated that stroke occurred after
discontinuing oral anticoagulant medication, especially NOACs,
which was independently associated with severe stroke at
presentation. Although NOACs offer many advantages for
long-term use in patients with NVAF, concerns of adhering
to or persisting with NOACs are warranted and physicians
should avoid discontinuation of NOACs for prolonged periods
(more than 7 days). The reason for NOAC and warfarin
withdrawal was unknown in 3 to 6 out of 10 patients with NVAF.
Our results revealed the potential harm of NOAC withdrawal
which may be useful for physicians to better educate patients and
improve the quality of anticoagulation therapy such that effective
prevention of thromboembolic events can be achieved in patients
with NVAF.
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